287 related articles for article (PubMed ID: 8932544)
41. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.
Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG
AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866
[TBL] [Abstract][Full Text] [Related]
42. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
Gill PS; Espina BM; Muggia F; Cabriales S; Tulpule A; Esplin JA; Liebman HA; Forssen E; Ross ME; Levine AM
J Clin Oncol; 1995 Apr; 13(4):996-1003. PubMed ID: 7707129
[TBL] [Abstract][Full Text] [Related]
43. Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study.
Dalu D; Fasola C; Ammoni L; De Francesco D; Cona MS; Rota S; Ferrario S; Gambaro A; Tosca N; Piva S; La Verde N
J Chemother; 2021 Sep; 33(5):342-347. PubMed ID: 34060438
[TBL] [Abstract][Full Text] [Related]
44. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.
Moore JD; Dezube BJ; Gill P; Zhou XJ; Acosta EP; Sommadossi JP
Cancer Chemother Pharmacol; 2000; 46(3):173-9. PubMed ID: 11021733
[TBL] [Abstract][Full Text] [Related]
45. A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma.
Newell M; Milliken S; Goldstein D; Lewis C; Boyle M; Dolan G; Ryan S; Cooper DA
Aust N Z J Med; 1998 Dec; 28(6):777-83. PubMed ID: 9972406
[TBL] [Abstract][Full Text] [Related]
46. Liposomal encapsulated anthracyclines: new therapeutic horizons.
Muggia FM
Curr Oncol Rep; 2001 Mar; 3(2):156-62. PubMed ID: 11177748
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
48. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
49. Cardiotoxicity after liposomal anthracyclines.
Young AM; Dhillon T; Bower M
Lancet Oncol; 2004 Nov; 5(11):654. PubMed ID: 15522651
[No Abstract] [Full Text] [Related]
50. Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin.
Masood R; Husain SR; Rahman A; Gill P
AIDS Res Hum Retroviruses; 1993 Aug; 9(8):741-6. PubMed ID: 8217343
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
52. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma.
Hengge UR; Brockmeyer NH; Baumann M; Reimann G; Goos M
Lancet; 1993 Aug; 342(8869):497. PubMed ID: 8102452
[No Abstract] [Full Text] [Related]
53. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
54. Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma.
Udhrain A; Skubitz KM; Northfelt DW
Int J Nanomedicine; 2007; 2(3):345-52. PubMed ID: 18019833
[TBL] [Abstract][Full Text] [Related]
55. Chemotherapy for AIDS-related and endemic African Kaposi's sarcoma in southern Africa.
Stein ME; Lachter J; Spencer D; Bezwoda WR
Int J Dermatol; 1995 Oct; 34(10):729-32. PubMed ID: 8537166
[TBL] [Abstract][Full Text] [Related]
56. Doxil offers hope to KS sufferers.
Prescott LM
J Int Assoc Physicians AIDS Care; 1995 Dec; 1(11):43-4. PubMed ID: 11363097
[TBL] [Abstract][Full Text] [Related]
57. Liposomal KS drugs approved.
GMHC Treat Issues; 1996 Apr; 10(4):8-9. PubMed ID: 11363710
[TBL] [Abstract][Full Text] [Related]
58. Liposomal doxorubicin (Doxil).
Porche DJ
J Assoc Nurses AIDS Care; 1996; 7(2):55-9. PubMed ID: 8679968
[No Abstract] [Full Text] [Related]
59. Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma.
Yokota K; Yotsumoto M; Muramatsu T; Saito M; Kamikubo Y; Ichiki A; Chikasawa Y; Bingo M; Hagiwara T; Amano K; Fukutake K
J Infect Chemother; 2020 Feb; 26(2):289-291. PubMed ID: 31537471
[TBL] [Abstract][Full Text] [Related]
60. Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions.
Hernández-Morales DE; Hernández-Zaccaro AE
Eur J Cancer Care (Engl); 2005 Jul; 14(3):264-6. PubMed ID: 15952971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
